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Abstract
Over the next decade, a new generation of vaccines will target the neglected
tropical diseases (NTDs). The goal of most NTD vaccines will be to reduce the
morbidity and decrease the chronic debilitating nature of these often-forgotten
infections - outcomes that are hard to measure in the traditional potency-testing
paradigm. The absence of measurable correlates of protection, a lack of
permissive animal models for lethal infection, and a lack of clinical indications
that do not include the induction of sterilizing immunity required us to
reconsider the traditional bioassay methods for determining vaccine potency.
Owing to these limitations, potency assay design for NTD vaccines will
increasingly rely on a paradigm where potency testing is one among many tools
to ensure that a manufacturing process yields a product of consistent quality.
This potency test is a bioassay using BALB/c mice, which evaluates the
immunogenicity of the vaccine at set time interval post manufacture. Herein, we
discuss the results of 12 month potency testing of Necator americanusglutathione-S- transferase-1 (Na-GST-1) vaccine. The Effective Dose 50 (ED50),
with its 95% fiducial limits (FL) for each time point was determined along with
the Relative Potency with its 95% FL for 3, 6, 9 and 12 months post manufacture.
Potency testing has shown that storage at 4° C decreases the ED50 and increases
the relative potency of Na-GST-1 vaccine. We proposed that the change in ED50
and relative potency coincide with higher affinity binding of the Na-GST-1 to the
Alhydrogel® that occurred during storage at 4° C. These preclinical results lay the
foundation for moving forward with Phase 1 clinical trial in Brazil.
Na-GST-1 Hookworm Vaccine

Methods
Cumulative curves were obtained from individual time points. Test (ANOVA) of
parallelism was performed by linearizing these cumulative curves 1. A global
standard reference curve with the 95% CI was generated using these
cumulative curves1. A response threshold was estimated using the above global
curve 1. The Na-GST-1 drug product was fractionated by groups to generate the
following doses.
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The terminal sera was pooled and stored at -80° C. Four-parameter logistic log
(4-PL) fit of the standard reference curve data generated by serial dilution of
standard reference serum on ELISA plate were plotted on a logistic-log scale.
The 4-parameter standard reference curves were generated at multiple time
points.
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Figure 3. Parallelism of linearized standard reference curves

Figure 6. ED50 using probit transformed percent responders

Ninety mice were divided into 9 groups. Mice were vaccinated Intraperitoneally using the above doses and the following bleed and vaccination
schedule.
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Figure 1. Standard Reference Curves
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Table 2. ED502 and Relative Potency2
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Methods
Potency testing was performed using Female Balb/c mice. This assay utilizes a
quantal response or the achievement of a threshold of murine IgG against NaGST-1 above which we could assign an individual serum as being ‘positive’. The
response threshold was obtained using the standard reference serum . We
developed a standard reference serum (SRS) that we assayed on each ELISA plate
as a standard reference curve.
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Figure 5. Response Threshold (Global Standard Reference Curve)

Results

Relative Potency

The above potency animal study was performed at 0, 3, 6, 9 and 12 months
post manufacturing. The probit transformation of the percentage of responders
on day 28 in each dose group were plotted against the log10-transformed dose
of Na-GST-1. ED50 (Effective Dose 50) was obtained using the graphical
interpolation as well as using the methods described in European
pharmacopeia2. Similarly, relative potency was calculated using the methods
described in European pharmacopeia2. Here, the relative potency compare the
potency (immunogenicity) of Na-GST-1 vaccine at time 3, 6, 9 and 12 months
post manufacture to that of its potency at time 0 month (time of release).

Standard Reference Serum was generated by vaccinating sixty Balb/c mice with
0.05µg Na-GST-1 + 80µg Alhydrogel® + 5µg CpG10104 intramuscularly using the
following vaccination and bleed schedule.
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Figure 2. Cumulative Standard Reference Curves

Results

Table 1. Study Design

Necator americanus glutathione-S-transferase-1 (Na-GST-1) is a 24-kDa protein
from N. americanus that has peroxidase activity and catalyzes the conjugation of
reduced glutathione to a variety of electrophiles. Na-GST-1 exhibits a high
affinity for heme in vitro. Because both heme and hematin contain oxidative
iron, they can generate toxic reactive oxygen species that damage parasite
structures. Hookworm GSTs may bind and detoxify heme and hematin
byproducts generated during the blood degradation process. The recombinant
polypeptide Na-GST-1 was expressed in Pichia pastoris. Na-GST-1 Hookworm
Vaccine Drug Product was formulated at 0.1 mg/ml of Na-GST-1 with 0.8 mg/ml
of Alhydrogel®. The cGMP manufactured vaccine was stored at 4° C.
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A cumulative response threshold of 5AU was estimated using the Global
Standard Reference Curve (Figure 5).
ED50 of the Na-GST-1 vaccine was found to be 16.49 µg, 5.57 µg, 6.67 µg,
4.22 µg and 6.26 µg at 0, 3, 6, 9 and 12 months post manufacture
respectively (Figure 6, Table 2).
Relative potency of Na-GST-1 vaccine was found to be 2.84, 2.35, 3.75
and 2.49 at 3, 6, 9 and 12 months post manufacture respectively (Figure 7,
Table 2).
The specification submitted in our IND states, “The criterion for
acceptance is that the 95% upper fiducial limit of the estimated relative
potency is not less than 0.5”.
The upper 95% fiducial limits of the relative potency at 3,6, 9 and 12
months post manufacture was found to be 4.45, 4.76, 5.98 and 3.75
respectively.
Conclusions
The Na-GST-1 vaccine gain potency within the first three months of its
storage at 4° C and remain immunogenic 12 months post manufacture.
We proposed that the gain in potency within the first three months
coincides with the higher affinity binding of the Na-GST-1 to the Alhydrogel®
that occurred during storage at 4° C.
The Na-GST-1 vaccine shows increased potency at each of the tested time
points compared to its potency at the time of manufacture.
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Figure 7. Relative Potency2
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